Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shaker A Mousa

Showing results (31-40 of 435) with videos related to

Pageof 44
Sort By:
Expert Review of Cardiovascular Therapy|March 20, 2004
Antithrombotics in thrombosis and cancerShaker A Mousa
Methods in Molecular Medicine|January 22, 2004
Tissue factor/VIIa in thrombosis and cancerShaker A Mousa
Methods in Molecular Medicine|January 22, 2004
Arixtra (fondaparinux sodium)Shaker A Mousa
Methods in Molecular Medicine|January 22, 2004
Oral thrombin inhibitor ximelagatranShaker A Mousa
Seminars in Thrombosis and Hemostasis|March 9, 2002
Anticoagulants in thrombosis and cancer: the missing linkShaker A Mousa
Cardiovascular Drug Reviews|June 5, 2004
Low-molecular-weight heparins in thrombosis and cancer: emerging linksShaker A Mousa
Journal of Cardiovascular Pharmacology|April 12, 2005
Alpha v integrin affinity/specificity and antiangiogenesis effect of a novel tetraaza cyclic peptide derivative, SU015, in various speciesShaker A Mousa
Cancers|June 24, 2022
Management of Pancreatic Cancer and Its Microenvironment: Potential Impact of Nano-TargetingNardeen Perko, Shaker A Mousa
Methods in Molecular Medicine|January 22, 2004
Antiplatelet, anticoagulant, and thrombolytic drug interactionsOmer Iqbal, Shaker A Mousa
Cancer Cell International|March 29, 2011
Therapeutics formulated to target cancer stem cells: Is it in our future?Stephanie Clayton, Shaker A Mousa
Pageof 44

Showing results (31-40 of 435) with videos related to

Sort By:
Pageof 44
Expert Review of Cardiovascular Therapy|March 20, 2004
Antithrombotics in thrombosis and cancerShaker A Mousa
Methods in Molecular Medicine|January 22, 2004
Tissue factor/VIIa in thrombosis and cancerShaker A Mousa
Methods in Molecular Medicine|January 22, 2004
Arixtra (fondaparinux sodium)Shaker A Mousa
Methods in Molecular Medicine|January 22, 2004
Oral thrombin inhibitor ximelagatranShaker A Mousa
Seminars in Thrombosis and Hemostasis|March 9, 2002
Anticoagulants in thrombosis and cancer: the missing linkShaker A Mousa
Cardiovascular Drug Reviews|June 5, 2004
Low-molecular-weight heparins in thrombosis and cancer: emerging linksShaker A Mousa
Journal of Cardiovascular Pharmacology|April 12, 2005
Alpha v integrin affinity/specificity and antiangiogenesis effect of a novel tetraaza cyclic peptide derivative, SU015, in various speciesShaker A Mousa
Cancers|June 24, 2022
Management of Pancreatic Cancer and Its Microenvironment: Potential Impact of Nano-TargetingNardeen Perko, Shaker A Mousa
Methods in Molecular Medicine|January 22, 2004
Antiplatelet, anticoagulant, and thrombolytic drug interactionsOmer Iqbal, Shaker A Mousa
Cancer Cell International|March 29, 2011
Therapeutics formulated to target cancer stem cells: Is it in our future?Stephanie Clayton, Shaker A Mousa
Pageof 44